Virus and antibody dynamics in acute west nile virus infection.

BACKGROUND The dynamics of the early stages of West Nile virus (WNV) infection can be assessed by follow-up studies of viremic blood donors. METHODS A total of 245 donors with WNV viremia were followed up weekly for 4 weeks and then monthly for up to 6 additional months or until seroconversion. Plasma samples were tested for WNV RNA by transcription-mediated amplification (TMA) and for WNV-specific IgM and IgG antibodies. RNA persistence was investigated by 6 replicate TMA tests; samples that were viremic for >40 days were tested for WNV-neutralizing activity. Follow up of 35 additional viremic donors for up to 404 days was conducted to evaluate persistence of WNV-specific antibody. RESULTS The median time from RNA detection to IgM seroconversion was 3.9 days; to IgG seroconversion, 7.7 days; to RNA negativity by single-replicate TMA, 13.2 days; and to RNA negativity by 6-replicate TMA, 6.1 additional days after results of single-replicate TMA are negative. For 4 donors in whom RNA persisted for >40 days after the index donation, all samples obtained after this threshold were also positive for WNV IgG and neutralizing activity. The mean times to IgM and IgA negativity were 156 and 220 days, respectively. CONCLUSIONS IgM and IgG develop rapidly after viremia and before RNA levels become undetectable, which occurred a mean of 13.2 days after the index donation among donors in this study. WNV RNA detection by replicate TMA rarely persists for >40 days after the index donation and is accompanied by WNV-specific neutralizing antibody, consistent with an absence of WNV transmission via transfusion of seropositive blood components.

[1]  Marion C Lanteri,et al.  Interferon and Interferon-Induced Chemokine Expression Is Associated with Control of Acute Viremia in West Nile Virus-Infected Blood Donors , 2008, The Journal of infectious diseases.

[2]  Rachel E. Owen,et al.  Comprehensive analysis of west nile virus-specific T cell responses in humans. , 2008, The Journal of infectious diseases.

[3]  J. L. Knight,et al.  Performance evaluation of the PROCLEIX® West Nile virus assay on semi‐automated and automated systems , 2007, Journal of medical virology.

[4]  I. Hewlett,et al.  West Nile virus adheres to human red blood cells in whole blood. , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[5]  M. Diamond,et al.  Cell-Specific IRF-3 Responses Protect against West Nile Virus Infection by Interferon-Dependent and -Independent Mechanisms , 2007, PLoS pathogens.

[6]  P. Mason,et al.  Early Production of Type I Interferon during West Nile Virus Infection: Role for Lymphoid Tissues in IRF3-Independent Interferon Production , 2007, Journal of Virology.

[7]  Theresa L. Smith,et al.  Transfusion‐associated transmission of West Nile virus, United States 2003 through 2005 , 2006, Transfusion.

[8]  M. Diamond,et al.  Gamma Interferon Plays a Crucial Early Antiviral Role in Protection against West Nile Virus Infection , 2006, Journal of Virology.

[9]  J. Fox,et al.  Nucleic acid testing for west nile virus RNA in plasma enhances rapid diagnosis of acute infection in symptomatic patients. , 2006, The Journal of infectious diseases.

[10]  B. Custer,et al.  West Nile Virus Infections Projected from Blood Donor Screening Data, United States, 2003 , 2006, Emerging infectious diseases.

[11]  S. Stramer,et al.  Self‐reported symptoms associated with West Nile virus infection in RNA‐positive blood donors , 2006, Transfusion.

[12]  B. Custer,et al.  The Cost-Effectiveness of Screening the U.S. Blood Supply for West Nile Virus , 2005, Annals of Internal Medicine.

[13]  M. Busch,et al.  Development and Persistence of West Nile Virus-Specific Immunoglobulin M (IgM), IgA, and IgG in Viremic Blood Donors , 2005, Journal of Clinical Microbiology.

[14]  Peter Tomasulo,et al.  Screening the blood supply for West Nile virus RNA by nucleic acid amplification testing. , 2005, The New England journal of medicine.

[15]  G. Foster,et al.  West Nile Virus Among Blood Donors in the United States, 2003 and 2004 , 2005, The New England journal of medicine.

[16]  S. Glynn,et al.  The 2003 West Nile virus United States epidemic: the America's Blood Centers experience , 2005, Transfusion.

[17]  M. Drebot,et al.  Analytical and clinical sensitivity of West Nile virus RNA screening and supplemental assays available in 2003 , 2005, Transfusion.

[18]  E. Hayes,et al.  Westward ho?--The spread of West Nile virus. , 2004, The New England journal of medicine.

[19]  P. Tomasulo,et al.  Triggers for switching from minipool testing by nucleic acid technology to individual‐donation nucleic acid testing for West Nile virus: Analysis of 2003 data to inform 2004 decision making , 2004, Transfusion.

[20]  Roderick C. Jones,et al.  Clinical Characteristics and Functional Outcomes of West Nile Fever , 2004, Annals of Internal Medicine.

[21]  Sally Caglioti,et al.  Detection of HIV-1 and HCV infections among antibody-negative blood donors by nucleic acid-amplification testing. , 2004, The New England journal of medicine.

[22]  W. Fawzi,et al.  Late postnatal transmission of HIV-1 in breast-fed children: an individual patient data meta-analysis. , 2004, The Journal of infectious diseases.

[23]  Shin Ta Liu,et al.  SAS® Survival Analysis Techniques for Medical Research , 2004, Technometrics.

[24]  A. Bagić,et al.  West Nile Virus: Pathogenesis and Therapeutic Options , 2004, Annals of Internal Medicine.

[25]  D. Descamps,et al.  Estimating and Comparing Reduction in HIV-1 RNA in Clinical Trials Using Methods for Interval Censored Data , 2004, Journal of acquired immune deficiency syndromes.

[26]  R. Dodd Emerging infections, transfusion safety, and epidemiology. , 2003, The New England journal of medicine.

[27]  R. Lanciotti,et al.  Transmission of West Nile virus through blood transfusion in the United States in 2002. , 2003, The New England journal of medicine.

[28]  W. Hogrefe,et al.  Detection of West Nile Virus (WNV)-Specific Immunoglobulin M in a Reference Laboratory Setting during the 2002 WNV Season in the United States , 2003, Clinical Diagnostic Laboratory Immunology.

[29]  Denise A. Martin,et al.  Persistence of Virus-Reactive Serum Immunoglobulin M Antibody in Confirmed West Nile Virus Encephalitis Cases , 2003, Emerging infectious diseases.

[30]  L. Petersen,et al.  West Nile Virus: A Primer for the Clinician , 2002, Annals of Internal Medicine.

[31]  Denise A. Martin,et al.  Use of Immunoglobulin M Cross-Reactions in Differential Diagnosis of Human Flaviviral Encephalitis Infections in the United States , 2002, Clinical and Vaccine Immunology.

[32]  V. Carey,et al.  Mixed-Effects Models in S and S-Plus , 2001 .

[33]  A. Hannigan,et al.  A Re-analysis of a Caries Clinical Trial by Survival Analysis , 2001, Journal of dental research.

[34]  D. Bates,et al.  Mixed-Effects Models in S and S-PLUS , 2001 .

[35]  J C Lindsey,et al.  Tutorial in biostatistics methods for interval-censored data. , 1998, Statistics in medicine.

[36]  T. Mazzulli,et al.  [Diagnosis of viral infections]. , 1976, Wiener medizinische Wochenschrift.

[37]  B. Turnbull The Empirical Distribution Function with Arbitrarily Grouped, Censored, and Truncated Data , 1976 .

[38]  T. Mazzulli,et al.  Diagnosis of Viral Infections , 2009 .

[39]  J. Stockman The Cost-Effectiveness of Screening the US Blood Supply for West Nile Virus , 2007 .

[40]  Transfusion-associated transmission of West Nile virus--Arizona, 2004. , 2004, MMWR. Morbidity and mortality weekly report.

[41]  M. Harlow Food and Drug Administration Center for Biologics Evaluation and Research , 2003 .

[42]  S. Ruță,et al.  Evaluation of immunoglobulin M (IgM) and IgG enzyme immunoassays in serologic diagnosis of West Nile Virus infection. , 2000, Journal of clinical microbiology.

[43]  C. Southam,et al.  Induced virus infections in man by the Egypt isolates of West Nile virus. , 1954, The American journal of tropical medicine and hygiene.

[44]  Fitting linear mixed-effects models , 2022 .